chevron_leftBack
As of 13 June 2026, OnKure Therapeutics, Inc. has a market cap of $206.62M USD, ranking #20861 globally and #3409 in the United States.
It ranks #1872 in the Healthcare sector, and #680 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$206.62MUSD
Enterprise Value
$148.12MUSD
EBITDA (TTM)
-$62.5MUSD
Net Income (TTM)
-$59.52MUSD
PB Ratio
1.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Nicholas Saccomano
open_in_new
Employees
45
Founded
2011
Website
onkuretherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2% | 4.9% | 28% | 81% | 54% | 102% |
News
Loading...
OKUR Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
OKUR
OnKure Therapeutics Inc Class A Shares
ISIN: US68277Q1058
Shares Out.:
Shares Outstanding:
40.396M1
Shares Float:
29.167M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
5.12 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
369K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
265K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
174K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
133K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
72K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
57K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
156K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
140K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
133K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
88K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
53K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
52K%
80.96B GBP
|
14.6
|
chevron_leftBack